Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Medicenna Therapeutics Corp. (MDNA : NSDQ)
 
 • Company Description   
Medicenna Therapeutics Corp is a clinical stage immuno-oncology company. It is engaged in developing engineered versions of IL-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines ECs for the treatment of cancer. Medicenna Therapeutics Corp is based in Toronto, Canada.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.96 Daily Weekly Monthly
20 Day Moving Average: 114,839 shares
Shares Outstanding: 56.00 (millions)
Market Capitalization: $53.94 (millions)
Beta: 1.04
52 Week High: $4.02
52 Week Low: $0.91
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -16.60% -8.68%
12 Week -39.03% -31.48%
Year To Date -40.90% -27.80%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
200-1920 Yonge Street
-
Toronto,A6 M4S 3E2
CAN
ph: 416-648-5555
fax: 416-572-7501
ir@medicenna.com http://www.medicenna.com
 
 • General Corporate Information   
Officers
Fahar Merchant - Chief Executive Officer; Chairman and President
Elizabeth Williams - Chief Financial Officer
Rosemina Merchant - Director
Albert Beraldo - Director
Chandra Panchal - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 58490H107
SIC: 2834
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 05/27/22
Share - Related Items
Shares Outstanding: 56.00
Most Recent Split Date: (:1)
Beta: 1.04
Market Capitalization: $53.94 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.07 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.34 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/27/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.65
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 12.50%
vs. Previous Quarter: 41.67%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©